IDEAYA Biosciences, Inc.
IDYAUnited States
30 filed reports · 262 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
30 reports · Jun 2019 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 22 | 2,906 | Jun 2019 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 7 | 2,322 | Dec 2019 to Dec 2025 |
| Quarterly · 10-Q/ASEC EDGAR | 1 | 2 | Mar 2024 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 4, 2026 | 296 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 5, 2026 | 196 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 17, 2026 | 600 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 4, 2025 | 187 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 5, 2025 | 128 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 6, 2025 | 116 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Feb 18, 2025 | 288 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Nov 4, 2024 | 134 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 6, 2024 | 121 | Open |
| FY2024 Q1 | 10-Q/A | Mar 31, 2024 | Aug 6, 2024 | 2 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 7, 2024 | 121 | Open |
| FY2023 | 10-K | Dec 31, 2023 | Feb 20, 2024 | 288 | Open |
Financial data
262 concepts · 5,230 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial260 concepts · 5,165 facts · Dec 2015 to Jul 2026
- Stockholders equity (US GAAP)46 · Dec 2016 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents45 · Dec 2016 to Jun 2026
- Cash and cash equivalents at carrying value43 · Dec 2017 to Jun 2026
- Net income loss43 · Dec 2017 to Jun 2026
- Operating expenses (US GAAP)43 · Dec 2017 to Jun 2026
- Restricted cash43 · Dec 2017 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value42 · Dec 2017 to Jun 2026
- Allocated share based compensation expense42 · Dec 2017 to Jun 2026
- Comprehensive income net of tax42 · Dec 2017 to Jun 2026
- Depreciation and amortization42 · Dec 2017 to Jun 2026
- General and administrative expense (US GAAP)42 · Dec 2017 to Jun 2026
- Operating income loss42 · Dec 2017 to Jun 2026
- Other comprehensive income loss net of tax portion attributable to parent42 · Dec 2017 to Jun 2026
- Research and development expense42 · Dec 2017 to Jun 2026
- Accretion amortization of discounts and premiums investments41 · Dec 2017 to Jun 2026
- Capital expenditures incurred but not yet paid41 · Dec 2017 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect41 · Dec 2017 to Jun 2026
- Depreciation depletion and amortization41 · Dec 2017 to Jun 2026
- Income tax expense benefit41 · Jun 2018 to Jun 2026
- Increase decrease in accounts payable41 · Dec 2017 to Jun 2026
- Increase decrease in accrued liabilities and other operating liabilities41 · Dec 2017 to Jun 2026
- Increase decrease in prepaid deferred expense and other assets41 · Dec 2017 to Jun 2026
- Net cash provided by used in financing activities41 · Dec 2017 to Jun 2026
- Net cash provided by used in investing activities41 · Dec 2017 to Jun 2026
Product2 concepts · 65 facts · Dec 2022 to Jun 2026
- Darovasertib64 · Dec 2022 to Jun 2026
- Contract with customer liability revenue recognized1 · Dec 2022
Segments
65 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or service8 members · 65 facts
- Darovasertib14 · Dec 2022 to Jun 2026
- IDE16114 · Dec 2022 to Jun 2026
- IDE39714 · Dec 2022 to Jun 2026
- IDE8497 · Dec 2024 to Jun 2026
- IDE0345 · Mar 2025 to Jun 2026
- IDE5745 · Mar 2025 to Jun 2026
- IDE8925 · Mar 2025 to Jun 2026
- Methionine Adenosyl Transferase2 A Program Supply1 · Dec 2022
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.